Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation

Journal of Hypertension

Volumn 23, Issue 9, 2005, Pages 1609-1616

  Morales, José M ^a   Dominguez Gil, Beatriz ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cardiovascular disease; Cardiovascular mortality; Corticosteroids; Cyclosporine; Renal transplantation; Sirolimus; Tacrolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS;

BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG POTENTIATION; DRUG WITHDRAWAL; GLUCOSE INTOLERANCE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY GRAFT; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 24144459534     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000180159.81640.2f     Document Type: Review

References (73)

1. Wolfe RA, Ashby UB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
2. Ojo Ao, Hanson JA, Meier-Kriesche H-U, Okechukwu CN, Wolfe RA, Leichtman AB, et al. Survival in recipients of marginal cadaveric donors kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12:589-597.
3. Serón D, Arias M, Campistol JM, Morales JM, for the Spanish Chronic Allograft Nephropathy Study Group. Late renal allograft failure between 1990-1998 in Spain: a changing scenario. Transplantation 2003; 76:1588-1594.
4. Kasiske BL. Cardiovascular risk factors associated with immunosuppression in renal transplantation. Available at web site http://www.scientific- frontiers1.com/6010/slides/index.asp. Accessed June 2004.
5. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (suppl 3):112-119.
6. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4 (suppl 1):30-38.
7. Textor SC, Canzanello VJ, Teler SJ, Wilson DJ, Schwartz LL, Augustine JE, et al. Cyclosporine induced hypertension after transplantation. Mayo Clin Proc 1994; 69:1182-1193.
8. Morales JM, Andrés A, Rengel M, Rodicio JL. Influence of cyclosporine, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 (suppl 1):121-124.
9. Zeier M, Mandelbaum A, Ritz E. Hypertension in the transplanted patient. Nephron 1998; 80:257-268.
10. Opelz G, Wujciak T, Ritz E, for the Collaborative Transplant Study Group. Association of kidney graft failure with recipient blood pressure. Kidney Int 1998; 53:217-222.
11. Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int 2002; 62 (suppl 82):81-87.
12. Domínguez-Gil B, Espejo B, Muñoz MA, Morales JM. Hipertensión arterial después del trasplante renal. Hipertensión 2002; 19:80-90.
13. Hricik DE, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant patients. Transplantation 1992; 53:1232-1236.
14. Vanrenterghem Y, Van Hoof JP, Squifflet JP, Salmela K, Rigotti P, Jindal RM, et al., for The European Tacrolimus/MMF Renal Transplantation Study Group. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5:87-95.
15. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70:1352-1359.
16. Campistol JM, Romero R, Paul J, Gutierrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 (suppl 3):iii62-iii66.
17. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73:775-782.
18. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359:741-746.
19. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12:368-373.
20. Artz MA, Boots JMM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4:937-945.
21. Klein IH, Abrahams A, Van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal haemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73:732-736.
22. Chueh SC, Kahan B. Clinical application of sirolimus in renal transplantation: an update. Transpl Int 2005; 18:261-277.
23. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2:436-440.
24. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777-781.
25. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant 2002; 17 (suppl 4):25-26.
26. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-185.
27. Boots JMM, Christiansen MHL, Van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients. Drugs 2004; 64:2047-2073.
28. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829-839.
29. Roth D, Milgrom M, Esquenazi V, Fuller L, Burke G, Miller J. Posttransplant hyperglycemia: increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47:278-281.
30. Yamamoto H, Akazawa S, Yamaguchi Y, Yokota A, Yamasaki H, Nakanishi T, et al. Effects of cyclosporine A and low dosages of steroid on posttransplantation diabetes in kidney transplant recipients. Diabetes Care 1991; 14:867-870.
31. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, et al. β-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes melllitus. Transplantation 2001; 71:1417-1423.
32. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977-983.
33. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64:436-443.
34. Ahsan N, Johnson C, Gonwa T, Halloran P, Stegall M, Hardy M, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72:245-250.
35. Romagnoli J, Citterio F, Violi P, Nanni G, Castagneto M. Posttransplant diabetes mellitus after kidney transplantation with different immunosuppressive agents. Transplant Proc 2004; 36:690-691.
36. Trompeter R, Filler G, Webb NJ, Klinger M, Friman S, Scheuermann EH, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17:141-149.
37. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25:583-592.
38. Short CD, Torregrosa V, Nicholson M, Bakran A, Cambi V. Immunosuppressive monotherapy after kidney transplantation: comparison between tacrolimus and cyclosporine-microemulsion. Am J Transplant 2003; 3 (suppl 5):220 (Abstract 268).
39. Van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13:213-220.
40. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13:221-227.
41. Kasiske BL. Risk factors for accelerated atheroclerosis in renal transplant recipients. Am J Med 1988; 84:985-992.
42. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14:648-654.
43. Kasiske BL, Guijarro C, Massy ZA. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7:158-165.
44. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024-2031.
45. Rayyes OA, Wallmark A, Floren CH. Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology 1996; 24:613-619.
46. Artz MA, Boots JMM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14:1880-1888.
47. Martinez Castelao A, Ramos R, Serón D, Gil-Vernet S, Fiol C, Gomez-Gerique N, et al. Effect of cyclosporine and tacrolimus on lipoprotein oxidation after renal transplantation. Nefrología 2002; 22:364-369.
48. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection. A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356:194-202.
49. Macdonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271-280.
50. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036-1042.
51. Kreis H, Cisterne JM, Land H, Wramner L, Squifflet JP, Abramowicz D, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252-1260.
52. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72:1244-1250.
53. Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S, Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75:1213-1220.
54. Nungaray N, Arriola M, Gutierrez MJ, Hernandez E, Gonzalez E, Andres A, Morales JM. Rapamycin at six years can exhibit normal renal function without proteinuria or neoplasia after renal transplantation. A single center experience. Transplant Proc 2005 (in press).
55. Curtis JJ, Dubovsky E, Whelchel JD, Diethelm AG, Whelchel JD, Jones P. Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 328:477-479.
56. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000; 69 (suppl 12):5-10.
57. Jurewicz WA. Tacrolimus versus cyclosporine immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 (suppl 1):7-11.
58. Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75:2048-2053.
59. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA. Molecular and structural consequences of early allograft injury. Kidney Int 2002; 61:686-696.
60. Gill JS, Tonelli M, Mix CH, Johnson N, Pereira BJ. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 2004; 65:692-699.
61. Cantarovich D, Renou M, Megnigbeto A, Giral-Classe M, Hourmant M, Dantal J, et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine induced adverse events. Transplantation 2005; 79:72-78.
62. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77:1457-1459.
63. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
64. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12:1059-1065.
65. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15:809-817.
66. Grinyo JM, Campistol JM, Paul J, Garcia-Martinez J, Morales JM, Prats D, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4:1308-1314.
67. Morales JM, Grinyo JM, Campistol JM, Garcia J, Arias M, Paul J, Prats D. FK506 withdrawal from a regimen of sirolimus plus FK506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [Abstract]. Am J Transplant 2005; 5 (suppl):460.
68. Wison PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
69. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11:1735-1743.
70. Kramer BK, Zulke C, Kammerl MC, Schmidt C, Hengstenberg C, Fischereder M, et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3:982-987.
71. Morales JM. Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. Kidney Int 2005; 67 (suppl 93):69-73.
72. Blum CB. Effects of sirolimus on lipids in renal allograft recipients. An analysis using the Framingham risk model. Am J Transplant 2002; 2:551-559.
73. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.